Bio-Link Australia in Blackburn, Victoria, Australia | Local service

Bio-Link Australia

Locality: Blackburn, Victoria, Australia

Address: Level 1, 108 South Parade 3130 Blackburn, VIC, Australia

Website: http://bio-link.com

Likes: 38

Add/Update information

Reviews

Tags

• Local service
• Biotechnology company

24.01.2022 Biotechnology companies looking to close a licensing, acquisition or investment deal need to be prepared for a potential buyer's due diligence team. A virtual data room provides a secure place in which to host and share your confidential company information with potential buyers or investors, enabling quick and controlled data disclosure. Key documents are centralised and curated to facilitate due diligence and accelerate the deal process. Learn more about how Bio-Link can set up and manage your secure virtual data room: https://goo.gl/r2NTa4

18.01.2022 Bio-Link has been engaged by Neural Diagnostics to facilitate licensing and commercial development of EVestG, a new technology for the direct, objective and physiologically relevant classification of neurological conditions. EVestG is non-invasive and allows accurate and rapid classification of neurological diseases including Alzheimer's, Parkinson's, bipolar affective disorder, depression, Menière's disease and schizophrenia. As a complimentary assessment tool and potential companion diagnostic, EVestG can be utilised to streamline and accelerate clinical development of CNS drugs. Review a summary of the technology: https://goo.gl/9XnMLj.

18.01.2022 Congratulations to Actinogen Medical for their breakthrough results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial! Their results show a significant improvement in cognition in trial participants dosed with Xanamem 20mg daily for 12 weeks, compared to placebo. These are the results we have been looking for. They are hugely important for the development of Xanamem and for the potential for Xanamem to treat Alzheimer’s disease and other conditions associated with cognitive impairment - Actinogen CEO Dr Bill Ketelbey

17.01.2022 Are you interested in global business development for your company? Join us at AusBiotech’s annual conference, #AusBio19, and meet Bio-Link's Lilly Bojarski, Senior Business Development Associate. We can help you with all aspects of business development, including commercialisation, deal negotiation and project management. Learn more: https://bit.ly/2BSAki2 #biotechnology

16.01.2022 We are delighted to welcome Kate Samardzic to the Bio-Link team as a Business Development Associate. Learn more about Kate and the rest of the Bio-Link team: http://bio-link.com/team/ #biotechnology

14.01.2022 Bio-Link's Christos Papadimitriou and Lilly Bojarski have been selected for the MTPconnect Bridge Program 2018, which offers strategic professional training to advance skills necessary to boost the commercialisation of Australian innovative research and biotechnologies. Bio-Link is pleased to be represented for a second year, following the inauguration of the initiative in 2017 (https://goo.gl/ztmUVA).

12.01.2022 What a week and a whole lot of shoe leather! Bio-Link was delighted to represent our client, Actinogen Medical, at #JPM2020. Bio-Link’s Christian Toulli and Actinogen CEO Bill Ketelbey travelled over 31 km (generally on foot) around San Francisco, meeting with leading pharma executives, sharing the latest exciting data and future strategy for the development of #Xanamem for Alzheimer’s disease and other neurological diseases associated with cognitive impairment.

11.01.2022 Lasker Foundation has announced the winners of their 2019 #LaskerAwards. These great researchers join an elite list of recipients that are truly amazing! You may recognise many of those names, including Herbert Boyer, Tom Cech, Kohler and Milstein, Francis Crick, Jonas Salk and many other of the world's most accomplished researchers. Many of them wrote the textbooks you studied, some of them may have even been your supervisors or theirs. Talk about making a mark! Max D. Coop...er and Jaques Miller (top right down) won the 2019 Albert Lasker Basic Medical Research Award for B and T cells the organising principle of the adaptive immune system. Dennis J. Slamon, Axel Ullrish and H. Michael Shepard (bottom left to right) won the 2019 Lasker - DeBakey Clinical Medical Research Award for Herceptin a targeted antibody therapy for breast cancer. Gavi, the Vaccine Alliance (bottom right corner) won the 2019 Lasker Bloomberg Public Service Award for Providing sustained access to childhood vaccines around the globe. Find out more: Laskerfoundation.org/awards/

08.01.2022 Bio-Link is excited to announce our new partnership with CCRM Australia. They are a not for profit organisation established by Australia’s leading regenerative medicine researchers and companies to accelerate the translation and commercialisation of regenerative medicine discoveries. #LifeSciences

06.01.2022 Bridging the gap between science & business. Don’t miss out on the inaugural Business of Regenerative Medicine Asia Pacific Symposium co-hosted by Bio-Link partner CCRM Australia and the New South Wales Stem Cell Network. The Symposium is a great opportunity to join the field’s leading organisations, industry players and business talent, and discover how to accelerate #commercialisation of #regenerativemedicine. Register NOW to secure your spot! (Limited tickets availabl...e) Register: https://bit.ly/2NbAG9K

05.01.2022 We’ve been silent for a while but now we’re back! Here’s a taste of the content we have been posting on LinkedIn. How would you like us to contribute to Facebook?

05.01.2022 Check out Bio-Link Australia Executive Director Christian Toouli’s article The Sacred Word: De-risking biotech messaging in the new edition of the Australasian Biotechnology journal: https://bit.ly/31tdOa9 #Biotechnology About Australasian Biotechnology: ... Australasian Biotechnology is AusBiotech’s official journal, bringing us the latest news in biotechnology research and business. AusBiotech is Australia’s Biotechnology Industry Organisation, a not-for-profit limited guarantee company representing over 3000 members in the life sciences arena, dedicated to the development, growth and prosperity of the Australian Biotechnology Industry.

02.01.2022 #Cancer patients may now receive earlier access to products with the U.S. Food and Drug Administration’s new initiative, #ProjectOrbis. This new development is a collaboration among international regulators to review cancer products concurrently in different countries, eliminating significant regulatory submission delays a product would usually otherwise have. Patients suffering from advanced endometrial carcinoma now have access to Lenvima (lenvatinib) and Keytruda (pembrolizumab), thanks to the first action of Project Orbis, undertaken by the FDA, Australian Therapeutic Goods Administration - TGA and Health Canada. Find out more about Project Orbis: https://bit.ly/2kmwl8x